Who is sponsoring NCT03988686?

NCT03988686 is sponsored by Fudan University.

What drugs are being tested in NCT03988686?

Interventions in NCT03988686: Radical prostatectomy plus standard care, Standard of care for metastatic prostate cancer.

What condition does NCT03988686 study?

NCT03988686 studies Prostate Cancer Metastatic.

Is NCT03988686 still recruiting?

NCT03988686 is currently status unknown. Last updated 17 June 2019.

Last reviewed 2019-06-17 · How we verify

NCT03988686

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Testing Radical Prostatectomy in Chinese Men With Prostate Cancer and oligoMetastases to the Bone

Status unknown NA Last updated 17 June 2019

What this trial tests

NA trial testing Radical prostatectomy plus standard care in Prostate Cancer Metastatic in 120 participants. Status unknown.

Timeline

1 April 2019

Primary endpoint
31 March 2021

31 March 2022

Quick facts

Lead sponsor	Fudan University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	120
Start date	1 April 2019
Primary completion	31 March 2021
Estimated completion	31 March 2022
Sites	1 location across China

Drugs / interventions tested

Radical prostatectomy plus standard care
Standard of care for metastatic prostate cancer — full drug profile →

Conditions studied

Prostate Cancer Metastatic — all drugs for Prostate Cancer Metastatic →

Sponsor

Fudan University

Who can join

Adults 18 to 75, male only, with Prostate Cancer Metastatic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is to examine whether radical prostatectomy can impact survival and quality-of-life in men with oligo-metastatic prostate cancer.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer.
Preisser F, Chun FK, Banek S, Wenzel M, et al · · 2021 · cited 20× · PMID 34692582 · DOI 10.1016/j.prnil.2020.12.003
A Systematic Review of Patients' Values, Preferences, and Expectations for the Treatment of Metastatic Prostate Cancer.
Connor MJ, Genie MG, Burns D, Bass EJ, et al · · 2022 · cited 15× · PMID 34977691 · DOI 10.1016/j.euros.2021.10.003
The current role of precision surgery in oligometastatic prostate cancer.
von Deimling M, Rajwa P, Tilki D, Heidenreich A, et al · · 2022 · cited 11× · PMID 36208497 · DOI 10.1016/j.esmoop.2022.100597
Metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news.
Berghen C, Joniau S, Vulsteke C, Albersen M, et al · · 2020 · cited 6× · PMID 32565889 · DOI 10.3332/ecancer.2020.1036
Primary Tumor Treatment in Oligometastatic Prostate Cancer: Radiotherapy Versus Radical Prostatectomy.
Knipper S, Graefen M. · · 2022 · cited 4× · PMID 35024634 · DOI 10.1016/j.euros.2021.06.015
The role of surgery in high risk and advanced prostate cancer: A narrative review.
Roy CSD, Sachdeva A, Kandaswamy GV, Rai BP. · · 2021 · cited 3× · PMID 33201799 · DOI 10.5152/tud.2020.20475

Verify or expand the search:

Other recruiting trials for Prostate Cancer Metastatic

Currently open trials in the same condition.

NCT07292168 — A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Ex · Phase 1, PHASE2 · recruiting
NCT06165302 — Exercise in Prostate Cancer · NA · recruiting
NCT07484971 — Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Prostate Cancers in Algeria · recruiting
NCT06972628 — Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617 · Phase 2 · recruiting
NCT07089550 — PSMA PET for Treatment Response evaLuation of systemIC Therapies in prostAte caNcer (PELICAN) · recruiting

Other Fudan University trials

Trials by the same sponsor.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03988686 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fudan University
Last refreshed: 17 June 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03988686.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing